



When you want fast & effective ...
Reach for Flunazine® or Flunazine®-S
 (flunixin meglumine) (flunixin meglumine)



Flunazine®
 (flunixin meglumine)
Injectable Solution
 50 mg/mL • Veterinary

FEATURES

- Indicated for cattle and horses
- 100 mL and 250 mL packaging
- Non-narcotic, non-steroidal

FUNCTIONS

IN HORSES:

- Recommended for inflammation & pain associated with musculoskeletal disorders and/or alleviating visceral pain associated with colic

IN CATTLE:

- Indicated for control of pyrexia (fever) associated with BRD, fever and inflammation associated with endotoxemia and fever associated with acute bovine mastitis

BENEFITS

- Fast, long-lasting & effective analgesic activity
- Safe non-narcotic NSAID with no adverse reactions when used as directed
- Versatile & potent pain relief for horses & cattle
- Trusted and well known NSAID – a “go-to” for many DVMs



Flunazine®-S
 (flunixin meglumine)
Injectable Solution
 50 mg/mL • Veterinary



FEATURES

- Indicated for use in swine (not indicated for breeding swine)
- 100 mL packaging
- Non-narcotic, non-steroidal

FUNCTIONS

IN SWINE:

- Indicated for control of pyrexia (fever) common with swine respiratory disease
- Maximum plasma concentration as soon as 0.4 hours post administration

BENEFITS

- Fast, effective analgesic activity
- Long-lasting effect measurable up to 18 hours after injection
- Safe non-narcotic NSAID with no contraindications when used as directed
- More potent pain relief compared to pentazocine, meperidine or codeine
- Trusted & well known NSAID compound – a “go-to” for many DVMs

ITEM NO.	PRODUCT DESCRIPTION	UNIT SIZE
1FLU003	Flunazine®	100 mL
1FLU004	(flunixin meglumine) Injectable Solution	250 mL
1FLU009	Flunazine®-S (flunixin meglumine) Injectable Solution	100 mL

Flunazine®

(flunixin meglumine)
INJECTABLE SOLUTION
50 mg/mL • Veterinary



INDICATIONS:

Horse - Flunazine® Injectable Solution is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.

Cattle - Flunazine® Injectable Solution is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. Flunazine® Injectable Solution is also indicated for the control of inflammation in endotoxemia.

RESIDUE WARNINGS:

Cattle must not be slaughtered for human consumption within 4 days of the last treatment. Milk that has been taken during treatment and for 36 hours after the last treatment must not be used for food. Not for use in dry dairy cows. A withdrawal period has not been established for this product in preparturient calves. Do not use in calves to be processed for veal. Not for use in horses intended for food. Approved only for intravenous administration in cattle. Intramuscular administration has resulted in violative residues in the edible tissues of cattle sent to slaughter.

PRECAUTIONS:

As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal and renal toxicity. Sensitivity to drug-associated adverse effects varies with the individual patient. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction.

Since many NSAIDs possess the potential to induce gastrointestinal ulceration, concomitant use of Flunazine® Injectable Solution with other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided or closely monitored.

Flunazine® is a Registered Trademark of Bimeda, Inc.

Horse - The effect of Flunazine® Injectable Solution on pregnancy has not been determined. Studies to determine activity of Flunazine® Injectable Solution when administered concomitantly with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring adjunctive therapy.

Cattle - Do not use in bulls intended for breeding, as reproductive effects of Flunazine® Injectable Solution in these classes of cattle have not been investigated. NSAIDs are known to have potential effects on both parturition and the estrous cycle. There may be a delay in the onset of estrus if flunixin is administered during the prostaglandin phase of the estrous cycle. The effects of flunixin on imminent parturition have not been evaluated in a controlled study. NSAIDs are known to have the potential to delay parturition through a tocolytic effect. Do not exceed the recommended dose.

ADVERSE REACTIONS:

In horses, isolated reports of local reactions following intramuscular injection, particularly in the neck, have been received. These include localized swelling, sweating, induration, and stiffness. In rare instances in horses, fatal or nonfatal clostridial infections or other infections have been reported in association with intramuscular use of flunixin meglumine. In horses and cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use.

The Product Information, Indications, Dosage & Administration, and Warning Statements as well as Material Safety Data Sheets (MSDS) may be found on our website www.bimedaus.com or by calling Bimeda customer service at 888-524-6332.

Flunazine®-S (flunixin meglumine) INJECTABLE SOLUTION

50 mg/mL • Veterinary

For intramuscular use in swine.
Not for use in breeding swine.



INDICATION:

Flunazine®-S (flunixin meglumine) Injectable Solution is indicated for the control of pyrexia associated with swine respiratory disease.

RESIDUE WARNINGS:

Swine must not be slaughtered for human consumption within 12 days of the last treatment.

PRECAUTIONS:

As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Patients at greatest risk for adverse events are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed.

Since many NSAIDs possess the potential to produce gastrointestinal ulceration, concomitant use of flunixin meglumine with other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided.

Not for use in breeding swine. The reproductive effects of Flunazine®-S (flunixin meglumine) Injectable Solution have not been investigated in this class of swine. Intramuscular injection may cause local tissue irritation and damage. In an injection-site irritation study, the tissue damage did not resolve in all animals by Day 28 post-injection. This may result in trim loss of edible tissue at slaughter.

Sound Byte

CHECK-OFF & ECHO NOTES

Identify if a rep has discussed Bimeda recently at the customer location.

(Dr. or Producer, have you recently visited with a representative regarding Flunazine® from Bimeda?)

If **Yes** – review understanding and key benefits

If **No** – discuss/detail/review features, functions, benefits
(DSR = Primary contact)

Confidence

Dr. (or producer) Flunixin meglumine provides solid benefits when addressing pain and inflammation associated with diseases or conditions in cattle, swine, and horses. I believe it is important for you to know the “flunixin meglumine” offering from Bimeda.

Invitation (neutral)

Let's review Flunazine® and Flunazine-S® from Bimeda

It's the customer's decision

... to determine if Bimeda's formulas for cattle, swine, and horses will provide you with additional value in managing inflammation and pain in the animals entrusted to your care.